Cargando…
Mulberrofuran G, a Mulberry Component, Prevents SARS-CoV-2 Infection by Blocking the Interaction between SARS-CoV-2 Spike Protein S1 Receptor-Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor
Despite the recent development of RNA replication-targeted COVID-19 drugs by global pharmaceutical companies, their prescription in clinical practice is limited by certain factors, including drug interaction, reproductive toxicity, and drug resistance. COVID-19 drugs with multiple targets for the SA...
Autores principales: | Kim, Young Soo, Kim, Buyun, Kwon, Eun-Bin, Chung, Hwan-Suck, Choi, Jang-Gi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573737/ https://www.ncbi.nlm.nih.gov/pubmed/36235822 http://dx.doi.org/10.3390/nu14194170 |
Ejemplares similares
-
Mulberry Component Kuwanon C Exerts Potent Therapeutic Efficacy In Vitro against COVID-19 by Blocking the SARS-CoV-2 Spike S1 RBD:ACE2 Receptor Interaction
por: Kim, Young Soo, et al.
Publicado: (2022) -
Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2
por: Barker, Harlan, et al.
Publicado: (2020) -
Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator
por: Bian, Jingwei, et al.
Publicado: (2021) -
SARS-CoV-2, the Angiotensin Converting Enzyme 2 (ACE2) Receptor and Alzheimer’s disease
por: Lukiw, Walter J.
Publicado: (2021) -
Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2
por: Zhao, Xuesen, et al.
Publicado: (2020)